EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
   EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Corporate Action/Capital
   Increase
   Marinomed Biotech AG resolves capital increase excluding statutory
   subscription rights by issuing 154,053 no-par value bearer shares at an
   issue price of EUR 5 per share

   18-Sep-2024 / 17:21 CET/CEST
   Disclosure of an inside information acc. to Article 17 MAR of the
   Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS
   Group AG.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   Korneuburg, Austria, 18. September 2024 - Marinomed Biotech AG (the
   “Company”) announces that the Management Board has resolved today to
   increase the Company's share capital by EUR 154,053 to EUR 1,694,583 by
   issuing 154,053 new no-par value bearer shares against cash contributions.
   The new shares will be issued from the authorized capital 2024 and are
   subject to the direct exclusion of the statutory subscription rights of
   existing shareholders. The issue price per new share is EUR 5, so that the
   total issue price amounts to EUR 770,265. The Company's Supervisory Board
   approved this capital increase today, immediately after the Management
   Board passed the resolution.

   All 154,053 new shares have been subscribed at these issue terms and
   conditions by a total of eleven investors, including members of the
   Supervisory and Management Boards.

   The Company is continuing to negotiate with another investor regarding a
   possible second capital increase of a further 154,053 new shares to be
   issued from the authorized capital 2024, which would be issued in
   accordance with the authorization to exclude the statutory subscription
   rights of existing shareholders. The actual implementation of this second
   capital increase is dependent on the outcome of the specific negotiations
   with the investor, the conclusion of the respective transaction documents
   and the adoption of a resolution by the Company's Management Board and
   Supervisory Board. For the second capital increase, a report on the
   planned exclusion of statutory subscription rights must also be published
   at least two weeks before the required Supervisory Board resolution. In
   addition, the approval of the restructuring administrator (still pending
   for the second capital increase) is required due to the ongoing
   restructuring proceedings.

   +++ End of ad-hoc announcement +++

   End of Inside Information

   ══════════════════════════════════════════════════════════════════════════

   18-Sep-2024 CET/CEST News transmitted by EQS Group AG. www.eqs.com

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      office@marinomed.com
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
                Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
                (Official Market)
   EQS News ID: 1990689


    
   End of Announcement EQS News Service


   1990689  18-Sep-2024 CET/CEST

togel hari ini

togel hongkong

slot demo

pengeluaran hk

By adminn